Team Curis Group’s (TCG) service enables early detection of colon cancer using a high-sensitivity genetics-based test that requires only a small blood sample. TCG’s service is FDA-approved in both China and the US.   TCG’s product pipeline includes early detection of stomach, lung, pancreatic, liver and breast cancer.  TCG addresses the $50 billion genetic testing market to help individuals realize the vision of Precision Medicine and overall wellness.  TCG seeks to build the largest collection of human genomes to enable clinicians and consumers to obtain, understand, control (i.e. privacy), monetize and benefit from their genetic and medical data.  TCG is leveraging its channel to physicians to build out other genetics-based applications and services.

CEO: Eric Chen

Status:  Private

Company Headquarters:  Fremont, CA